FDA Plans Guidance This Year On Co-Development Of Diagnostics And Drugs
This article was originally published in The Gray Sheet
Executive Summary
FDA expects to complete a guidance document on co-development of diagnostics and drugs used for personalized medicine by the end of this year, FDA Commissioner Margaret Hamburg said at a meeting in Washington, D.C., Feb. 25
You may also be interested in...
New J&J Drug Candidates Don't Go It Alone: Companion Dx Are Standard
Johnson & Johnson's drug business could be a particularly productive partnering site for molecular diagnostics firms over the next several years, statements from one company executive suggest
New J&J Drug Candidates Don't Go It Alone: Companion Dx Are Standard
Johnson & Johnson's drug business could be a particularly productive partnering site for molecular diagnostics firms over the next several years, statements from one company executive suggest
New J&J Drug Candidates Don't Go It Alone: Companion Dx Are Standard
The drug giant is trying to partner with assay technology makers as early as possible in the development cycle, Centocor VP-biomarkers Dracopoli said at BIO.